Evidence map›Paper›PMID 37577760›Full record

ArticleThe EMBO journal2023

PTEN deficiency exposes a requirement for an ARF GTPase module for integrin-dependent invasion in ovarian cancer.

Konstantina Nikolatou, Emma Sandilands, Alvaro Román-Fernández, Erin M Cumming, Eva Freckmann, Sergio Lilla, Lori Buetow, Lynn McGarry, Matthew Neilson, Robin Shaw and 7 more

Open access · hybridAbstract read
In one paragraph

Article in The EMBO journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Konstantina NikolatouSchool of Cancer Sciences, University of Glasgow, Glasgow, UK.ORCID 0000-0002-5626-3390
Emma SandilandsSchool of Cancer Sciences, University of Glasgow, Glasgow, UK.ORCID 0000-0001-6829-0911
Alvaro Román-FernándezSchool of Cancer Sciences, University of Glasgow, Glasgow, UK.ORCID 0000-0002-5032-3460
Erin M CummingSchool of Cancer Sciences, University of Glasgow, Glasgow, UK.ORCID 0000-0002-6754-7583
Eva FreckmannSchool of Cancer Sciences, University of Glasgow, Glasgow, UK.ORCID 0000-0001-7880-180X
Sergio LillaThe CRUK Beatson Institute, Glasgow, UK.ORCID 0000-0003-3142-7640
Lori BuetowThe CRUK Beatson Institute, Glasgow, UK.ORCID 0000-0003-4951-8057
Lynn McGarryThe CRUK Beatson Institute, Glasgow, UK.ORCID 0000-0002-7055-2615
Matthew NeilsonThe CRUK Beatson Institute, Glasgow, UK.
Robin ShawThe CRUK Beatson Institute, Glasgow, UK.ORCID 0000-0001-5503-5233
David StrachanThe CRUK Beatson Institute, Glasgow, UK.
Crispin MillerThe CRUK Beatson Institute, Glasgow, UK.ORCID 0000-0003-4341-1283
Danny T HuangSchool of Cancer Sciences, University of Glasgow, Glasgow, UK.ORCID 0000-0002-6192-259X
Iain A McNeishDepartment of Surgery and Cancer, Ovarian Cancer Action Research Centre, Imperial College London, London, UK.ORCID 0000-0002-9387-7586
James C NormanSchool of Cancer Sciences, University of Glasgow, Glasgow, UK.ORCID 0000-0002-0098-3014
Sara ZanivanSchool of Cancer Sciences, University of Glasgow, Glasgow, UK.ORCID 0000-0002-9880-9099
David M BryantSchool of Cancer Sciences, University of Glasgow, Glasgow, UK.ORCID 0000-0003-2721-5012
Cancer Research UK Scotland Institute · GBOvarian Cancer Action · GB

Funding

ARF GTPase regulation of prostate tumorigenesis: spheroid and in vivo approachesK99CA163535 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BRYANT, DAVID MICHAEL · 2012 to 2013
$326k
Cancer Research UK 28291Cancer Research UK 29256Cancer Research UK 29800Cancer Research UK 29801Cancer Research UK A23278Cancer Research UK A28291Cancer Research UK A29800Cancer Research UK A29801Cancer Research UK C596/A17196Cancer Research UK C596/A19481Cancer Research UK C7932/A25170NCI NIH HHS K99 CA163535
6 · The paper itself

Abstract

Dysregulation of the PI3K/AKT pathway is a common occurrence in high-grade serous ovarian carcinoma (HGSOC), with the loss of the tumour suppressor PTEN in HGSOC being associated with poor prognosis. The cellular mechanisms of how PTEN loss contributes to HGSOC are largely unknown. We here utilise time-lapse imaging of HGSOC spheroids coupled to a machine learning approach to classify the phenotype of PTEN loss. PTEN deficiency induces PI(3,4,5)P

Indexed as

Monomeric GTP-Binding ProteinsOvarian NeoplasmsFemaleHumansIntegrinsPhosphatidylinositol 3-KinasesProteomicsPTEN PhosphohydrolaseIntegrinsMonomeric GTP-Binding ProteinsPhosphatidylinositol 3-KinasesPTEN PhosphohydrolasePTEN protein, human3D spheroidsARF6integrinsOvarian CancerPTEN

Identifiers

PMID37577760
PMCPMC10505920
OpenAlexW4385798998

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.